Biotinylated Human CD89 / FCAR Protein, His,Avitag™ (MALS verified)

用户评价
货号-规格
价格
Qty.
CD9-H82Eb-25ug
¥3675.00
CD9-H82Eb-200ug
¥14490.00
合计0件 产品金额¥ 0

产品详情

  • 分子别名(Synonym)

    CD89,FCAR,IgA Fc receptor

  • 表达区间及表达系统(Source)

    Biotinylated Human CD89 Protein, His,Avitag (CD9-H82Eb) is expressed from human 293 cells (HEK293). It contains AA Gln 22 - Asn 227 (Accession # P24071-1).

    Predicted N-terminus: Gln 22

    Request for sequence
  • 蛋白结构(Molecular Characterization)

    CD89 Structure

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 27.1 kDa. The protein migrates as 40-55 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • 标记(Labeling)

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • 蛋白标记度(Protein Ratio)

    Passed as determined by the HABA assay / binding ELISA.

  • 内毒素(Endotoxin)

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • 纯度(Purity)

    >95% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • 制剂(Formulation)

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • 重构方法(Reconstitution)

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • 存储(Storage)

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

推荐产品

数据展示

  • 电泳(SDS-PAGE)

    CD89 SDS-PAGE

    Biotinylated Human CD89 Protein, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    CD89 SEC-MALS

    The purity of Biotinylated Human CD89 Protein, His,Avitag (Cat. No. CD9-H82Eb) is more than 95% and the molecular weight of this protein is around 40-55 kDa verified by SEC-MALS.

    Report
  • 活性(Bioactivity)-ELISA

     CD89 ELISA

    Immobilized Human Anti-VP1 (NoV)-antibody-NORO-320, Human IgA2 | Human Kappa at 1 μg/mL (100 μL/well) can bind Biotinylated Human CD89 Protein, His,Avitag (Cat. No. CD9-H82Eb) with a linear range of 2-63 ng/mL (QC tested).

    Protocol

用户评价
发表评论

背景介绍

CD89 (FCAR) is a variably glycosylated 50-100 kDa myeloid-specific type I transmembrane (TM) Fc receptor for IgA that is a member of the multichain immune recognition receptor (MIRR) family. Human CD89 contains a 21 amino acid (aa) signal sequence and extracellular (ECD), TM and cytoplasmic domains of 206, 19 and 41 aa, respectively. Arg230 within the TM domain supports interaction with the ITAM-containing signaling subunit, FcR gamma, which contains a TM Asp . Two ECD C2-type Ig-like domains (EC1 and 2) are oriented at right angles. Up to two molecules of FCAR can bind one molecule of serum IgA via EC1. Many splice variants have been reported, but only two have been identified as proteins. The a.2 form, which lacks 22 aa just prior to the TM domain, is exclusively expressed in alveolar macrophages. The a.3 form lacks EC2. FCAR binds monomeric, polymeric and secretory IgA, but does not mediate the barrier function of secretory IgA in mucosal epithelium. CD89 (Fc alphaRI) is the human myeloid IgA Fc receptor expressed on cells, such as neutrophils, eosinophils and monocytes/macrophages. Cross-linking of CD89 on these cells, by IgA-opsonised particles (e.g. bacteria, viruses) or anti-CD89 monoclonal antibodies, can trigger various immunological effector functions which are generally protective but may also cause harm to the body.

前沿进展

 
药物研发进展
  • 英文全称:

    IgA Fc receptor

  • 中文全称:

    免疫球蛋白αFc受体

  • 种类:

  • 上市药物数量:

    0 详情

  • 临床药物数量:

    1 详情

  • 最高研发阶段:

    临床一期

联系我们
项目合作
查看更多项目
实验案例分析
查看更多案例分析
  • 产品基础信息
  • 产品详情
  • 推荐产品
  • 数据展示
  • 用户评价
  • 背景介绍